Clinical Data's Cogenics Division Announces Renewed DNA Sequencing Contract with Medical Research Council
NEWTON, Mass.--(BUSINESS WIRE)--June 5, 2006--Clinical Data, Inc. (NASDAQ: CLDA - News), a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as genetic tests to improve patient care, announced today that it is pleased to have been re-selected as an official supplier to the Medical Research Council (MRC) for DNA sequencing along with two other DNA sequencing companies. The Company's Cogenics division (formerly Lark Technologies) is the leading UK based provider of DNA sequencing to pharmaceutical, biotech and academic institutes with a long and successful history of working with the MRC.
Paul Tomlin, Director of European Operations, said, "We are very pleased to continue our relationship with the MRC and are confident of meeting the needs of MRC scientists across all 35 UK sites. Cogenics has over 17 years experience with DNA sequencing and other molecular biology services and as such is uniquely positioned to provide the best customer experience possible and to serve the needs of the MRC."
Cogenics provides comprehensive pharmacogenomics and molecular services to the scientific community with six sites across North America and Europe employing over 200 experienced scientists and other professionals. Cogenics' UK headquarters are based in a custom built facility in Takeley, Essex. By leveraging the latest in DNA sequencing technology, Cogenics provides an unrivalled quality of service, rapid turnaround and customer support. Cogenics also provides genotyping, gene expression, biobanking, extraction and other DNA and RNA services to numerous clients worldwide.
About Clinical Data, Inc.
Clinical Data, Inc. is a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as genetic tests to improve patient care. The Company, founded in 1972, is organized under three worldwide divisions segmented by service offerings and varying client constituents: PGxHealth(TM); Cogenics(TM); and Vital Diagnostics(TM). Clinical Data's Therapeutic Diagnostics(TM) division, PGxHealth, builds upon existing assets and know-how acquired from Genaissance Pharmaceuticals in the areas of genomics-based, genetic tests and therapeutic efficacy and safety biomarker development for drug utilization. PGxHealth plans to develop and introduce novel Therapeutic Diagnostics in some instances in combination with new and existing therapeutics. Clinical Data's Pharmacogenomics and Molecular Services(TM) division, Cogenics, consolidates the operations of Genaissance Pharmaceuticals, Inc., Lark Technologies, Inc. and Icoria, Inc., each acquired during 2005, and Genome Express SA, acquired in 2006. Cogenics provides a comprehensive range of molecular and pharmacogenomics services to pharmaceutical, biotech, academia, agricultural, and government clients. These services are offered in both research and regulated environments and have applications across the lifecycle of pharmaceutical product development including pharmacovigilance requirements post-launch. Clinical Data's Vital Diagnostics division consolidates the operations of Clinical Data Sales & Service, Inc., Vital Scientific NV, Vital Diagnostics Pty. Ltd., and Electa Lab s.r.l. This division serves the clinical laboratory in the traditional in-vitro diagnostics market worldwide with a focus on the physician's office, hospital and small-to-medium sized laboratory segments. With customers in approximately 100 countries, Vital Diagnostics has achieved a leading market share for instruments and reagents sold into moderately complex physicians' office laboratories within the United States. Clinical Data currently employs a staff of over 430. The Company is headquartered in Newton, Massachusetts with operations in Texas, Connecticut, RTP - North Carolina, Rhode Island, and California as well as internationally in the UK, France, the Netherlands, Italy and Australia. Furthermore, Clinical Data has numerous distribution, licensing, development and other collaborations with key partners. |
